Connect Biopharma Holdings Stock Performance
| CNTB Stock | USD 0.82 0.04 4.65% |
The firm shows a Beta (market volatility) of 1.12, which signifies a somewhat significant risk relative to the market. Connect Biopharma returns are very sensitive to returns on the market. As the market goes up or down, Connect Biopharma is expected to follow. At this point, Connect Biopharma has a negative expected return of -0.23%. Please make sure to confirm Connect Biopharma's maximum drawdown, as well as the relationship between the accumulation distribution and day typical price , to decide if Connect Biopharma performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Connect Biopharma Holdings has generated negative risk-adjusted returns adding no value to investors with long positions. Despite weak performance in the last few months, the Stock's basic indicators remain somewhat strong which may send shares a bit higher in April 2025. The current disturbance may also be a sign of long term up-swing for the company investors. ...more
1 | 3 US Penny Stocks With Market Caps Under 400M To Consider | 12/31/2024 |
2 | ABVC BioPharma and AiBtl BioPharmas Worldwide Business Development Team Participate in the 43rd Annual J.P. Morgan Healthcare Conference - Yahoo Finance | 01/16/2025 |
3 | WGS - GeneDx Holdings Corp. Latest Stock News Market Updates - StockTitan | 01/28/2025 |
4 | Connect Biopharma stock hits 52-week low at 0.91 amid market challenges - Investing.com | 02/18/2025 |
5 | Connect Biopharma Holdings And Two Other Promising Penny Stocks To Watch | 02/28/2025 |
6 | Connect Biopharma To Present At Leerink Partners Global Biopharma Conference Webcast At 140 PM ET - Nasdaq | 03/12/2025 |
| Begin Period Cash Flow | 79 M |
Connect |
Connect Biopharma Relative Risk vs. Return Landscape
If you would invest 106.00 in Connect Biopharma Holdings on December 17, 2024 and sell it today you would lose (20.00) from holding Connect Biopharma Holdings or give up 18.87% of portfolio value over 90 days. Connect Biopharma Holdings is currently does not generate positive expected returns and assumes 5.0004% risk (volatility on return distribution) over the 90 days horizon. In different words, 44% of stocks are less volatile than Connect, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Connect Biopharma Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Connect Biopharma's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Connect Biopharma Holdings, and traders can use it to determine the average amount a Connect Biopharma's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0455
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | CNTB |
Estimated Market Risk
| 5.0 actual daily | 44 56% of assets are more volatile |
Expected Return
| -0.23 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.05 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Connect Biopharma is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Connect Biopharma by adding Connect Biopharma to a well-diversified portfolio.
Connect Biopharma Fundamentals Growth
Connect Stock prices reflect investors' perceptions of the future prospects and financial health of Connect Biopharma, and Connect Biopharma fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Connect Stock performance.
| Return On Equity | -0.18 | ||||
| Return On Asset | -0.12 | ||||
| Profit Margin | (0.89) % | ||||
| Operating Margin | 0.25 % | ||||
| Current Valuation | (62.55 M) | ||||
| Shares Outstanding | 55.25 M | ||||
| Price To Book | 0.43 X | ||||
| Price To Sales | 1.96 X | ||||
| Gross Profit | 24.12 M | ||||
| EBITDA | (58.37 M) | ||||
| Net Income | (59.38 M) | ||||
| Cash And Equivalents | 1.28 B | ||||
| Cash Per Share | 23.26 X | ||||
| Total Debt | 465 K | ||||
| Debt To Equity | 0 % | ||||
| Current Ratio | 9.58 X | ||||
| Book Value Per Share | 2.00 X | ||||
| Cash Flow From Operations | (47.93 M) | ||||
| Earnings Per Share | (0.39) X | ||||
| Market Capitalization | 47.3 M | ||||
| Total Asset | 125.89 M | ||||
| Retained Earnings | (539.35 M) | ||||
| Working Capital | 96.71 M | ||||
About Connect Biopharma Performance
By analyzing Connect Biopharma's fundamental ratios, stakeholders can gain valuable insights into Connect Biopharma's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Connect Biopharma has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Connect Biopharma has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | -2 K | -2.1 K | |
| Return On Tangible Assets | (0.54) | (0.57) | |
| Return On Capital Employed | (0.70) | (0.74) | |
| Return On Assets | (0.43) | (0.45) | |
| Return On Equity | (0.68) | (0.64) |
Things to note about Connect Biopharma performance evaluation
Checking the ongoing alerts about Connect Biopharma for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Connect Biopharma help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Connect Biopharma generated a negative expected return over the last 90 days | |
| Connect Biopharma has high historical volatility and very poor performance | |
| Connect Biopharma has some characteristics of a very speculative penny stock | |
| Net Loss for the year was (59.38 M) with profit before overhead, payroll, taxes, and interest of 24.12 M. | |
| Connect Biopharma Holdings currently holds about 1.28 B in cash with (47.93 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 23.26, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 41.0% of the company shares are held by company insiders | |
| Latest headline from news.google.com: Connect Biopharma To Present At Leerink Partners Global Biopharma Conference Webcast At 140 PM ET - Nasdaq |
- Analyzing Connect Biopharma's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Connect Biopharma's stock is overvalued or undervalued compared to its peers.
- Examining Connect Biopharma's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Connect Biopharma's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Connect Biopharma's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Connect Biopharma's stock. These opinions can provide insight into Connect Biopharma's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Connect Stock analysis
When running Connect Biopharma's price analysis, check to measure Connect Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Connect Biopharma is operating at the current time. Most of Connect Biopharma's value examination focuses on studying past and present price action to predict the probability of Connect Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Connect Biopharma's price. Additionally, you may evaluate how the addition of Connect Biopharma to your portfolios can decrease your overall portfolio volatility.
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data |